Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells

Cancer Research

Volumn 68, Issue 12, 2008, Pages 4763-4773

  Yemelyanov, Alexander ^a   Czwornog, Jennifer ^a   Gera, Lajos ^b   Joshi, Sonali ^a,c   Chatterton Jr , Robert T ^a   Budunova, Irina ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; CORTICOTROPIN RELEASING FACTOR; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SALSOLA TUBERCULATIFORMIS EXTRACT; STEROID RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; 2 (4 ACETOXYPHENYL) 2 CHLORO N METHYLETHYLAMINE; 2-(4-ACETOXYPHENYL)-2-CHLORO-N-METHYLETHYLAMINE; ACETIC ACID DERIVATIVE; ANDROGEN; ANTIANDROGEN; AR PROTEIN, HUMAN; ETHYLAMINE; LUCIFERASE; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; DRUG BINDING; HUMAN; HUMAN CELL; HYDROGEN BOND; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; SALSOLA TUBERCULATIFORMIS; SHRUB; WESTERN BLOTTING; CELL CULTURE; CELL PROLIFERATION; CLONOGENIC ASSAY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; MALE; METABOLISM; PROSTATE TUMOR; RADIOASSAY; SYNTHESIS; TRANSACTIVATION;

ACETATES; ANDROGEN ANTAGONISTS; ANDROGENS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ETHYLAMINES; HUMANS; HYDROGEN BONDING; LUCIFERASES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOLIGAND ASSAY; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 49649107285     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6104     Document Type: Article

References (46)

1. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1:34-45.
2. Gabril MY, Duan W, Wu G, et al. A novel knock-in prostate cancer model demonstrates biology similar to that of human prostate cancer and suitable for preclinical studies. Mol Ther 2005;11:348-62.
3. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006;99:333-44.
4. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
5. Dondi D, Maggi R, Scaccianoce E, Martini L, Motta M, Poletti A. Expression and role of functional glucocorticoid receptors in the human androgen-independent prostate cancer cell line, DU145. J Mol Endocrinol 2001; 26:185-91.
6. Smith RG, Syms AJ, Nag A, Lerner S, Norris JS. Mechanism of the glucocorticoid regulation of growth of the androgen-sensitive prostate-derived R3327H-G8-A1 tumor cell line. J Biol Chem 1985; 260:12454-1263.
7. Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X, Budunova I. Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 2007;26:1885-96.
8. Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, Kihara K. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res 2006;12: 6012-7.
9. Nishimura K, Nonomura N, Satoh E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;93:1739-46.
10. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocr Rev 1999;20:435-59.
11. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002;96:23-43.
12. Wu W, Chaudhuri S, Brickley DR, Pang D, Karrison T, Conzen SD. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res 2004;64:1757-64.
13. De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003;24: 488-522.
14. Garside H, Stevens A, Farrow S, et al. Glucocorticoid ligands specify different interactions with NF-κB by allosteric effects on the glucocorticoid receptor DNA binding domain. J Biol Chem 2004;279:50050-9.
15. Greenstein S, Ghias K, Krett NL, Rosen ST. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res 2002;8:1681-94.
16. Chebotaev D, Yemelyanov A, Budunova I. The mechanisms of tumor suppressor effect of glucocorticoid receptor in skin. Mol Carcinogenesis 2007;46:732-40.
17. Kang Z, Janne OA, Palvimo JJ. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor. Mol Endocrinol 2004;18:2633-48.
18. Nelius T, Filleur S, Yemeyanov A, et al. Androgen receptor targets NF-κB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 2007;121:999-1008.
19. Swart P, Swart AC, Louw A, van der Merwe KJ. Biological activities of the shrub Salsola tuberculatiformis Botsch: contraceptive or stress alleviator? BioEssays 2003;25:612-9.
20. Louw A, Swart P. Salsola tuberculatiformis Botschantzev and an aziridine precursor analog mediate the in vivo increase in free corticosterone and decrease in corticosteroid-binding globulin in female Wistar rats. Endocrinology 1999;140:2044-53.
21. Tanner TM, Verrijdt G, Rombauts W, Louw A, Hapgood JP, Claessens F. Anti-androgenic properties of compound A, an analog of a non-steroidal plant compound. Mol Cell Endocrinol 2003;201:155-64.
22. Louw A, Swart P, Allie F. Influence of an aziridine precursor on the in vitro binding parameters of rat and ovine corticosteroid-binding globulin (CBG). Biochem Pharmacol 2000;59:167-75.
23. De Bosscher K, Vanden Berghe W, Beck IM, et al. Fully dissociated compound of plant origin for inflammatory gene repression. Proc Natl Acad Sci U S A 2005; 102:15827-32.
24. Song LN, Coghlan M, Gelmann EP. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol 2004;18:70-85.
25. Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 2006;13:653-66.
26. Hodgson MC, Astapova I, Cheng S, et al. The androgen receptor recruits nuclear receptor corepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005;280: 6511-9.
27. Honer C, Nam K, Fink C, et al. Glucocorticoid receptor antagonism by cyproterone acetate and RU486. Mol Pharmacol 2003;63:1012-20.
28. Bretschneider H. Phenylalkanolamines V. β-Chlorophenethylamine derivatives and their conversion into halogen-free compounds [in German]. Monatshefte fuer Chemie 1948;78:82-116.
29. Mulholland DJ, Cox M, Read J, Rennie P, Nelson C. Androgen responsiveness of Renilla luciferase reporter vectors is promoter, transgene, and cell line dependent. Prostate 2004;59:115-9.
30. Krishnan AV, Zhao XY, Swami S, et al. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 2002;143:1889-900.
31. Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2004;2:E274.
32. Kauppi B, Jakob C, Farnegardh M, et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 2003;278:2748-22754.
33. Thomsen R, Christensen MH. MolDock: a new technique for high-accuracy molecular docking. J Med Chem 2006;49:3315-21.
34. Stockner T, Sterk H, Kaptein R, Bonvin A. Molecular dynamics studies of a molecular switch in the glucocorticoid receptor. J Mol Biol 2003;328:325-34.
35. Hammer S, Spika I, Sippl W, et al. Glucocorticoid receptor interactions with glucocorticoids: evaluation by molecular modeling and functional analysis of glucocorticoid receptor mutants. Steroids 2003;68: 329-339.
36. Urushibara M, Ishioka J, Hyochi N, et al. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate 2007; 67:799-807.
37. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006;16:8598-607.
38. Hodgson MC, Astapova I, Hollenberg AN, Balk SP. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007;67:8388-95.
39. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002;277:26321-6.
40. Yemelyanov A, Gasparian A, Lindholm P, et al. Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 2006;25:387-98.
41. Tso CL, McBride WH, Sun J, et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J 2000;6:220-33.
42. Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 2007;275:109-17.
43. Reichardt HM, Kaestner KH, Tuckermann J, et al. DNA binding of the glucocorticoid receptor is not essential for survival. Cell 1998;93:531-41.
44. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002;296:2232-5.
45. De Bosscher K, Vanden Berghe W, Haegeman G. Cross-talk between nuclear receptors and nuclear factor κB. Oncogene 2006;25:6868-86.
46. Chebotaev D, Yemelyanov A, Lavker RM, Budunova I. Tumor suppressor effect of glucocorticoid receptor in skin is mediated via a decreased number and clonogenicity of epidermal stem cells. Oncogene 2007;26:3060-8.